Search research articles
Contact Us
Filters
Showing results (31-40 of 41) with videos related to
Page
of 5
Sort By:
Journal of Pain and Symptom Management
|
June 12, 2021
Acupuncture as an Adjunctive Treatment for Pain in Hospitalized Children With Sickle Cell Disease
Sarah Reece-Stremtan, Laila Mahmood, Stefanie Margulies, et al.
Environmental Research
|
December 5, 2024
The environmental neuroactive chemicals list of prioritized substances for human biomonitoring and neurotoxicity testing: A database and high-throughput toxicokinetics approach
Julia E Rager, Lauren E Koval, Elise Hickman, et al.
Environmental Research
|
March 10, 2026
Corrigendum to 'The environmental neuroactive chemicals list of prioritized substances for human biomonitoring and neurotoxicity testing: A database and high-throughput toxicokinetics approach' [Environ. Res. 2025 (266) 120537]
Julia E Rager, Lauren E Koval, Elise Hickman, et al.
Clinical Genitourinary Cancer
|
February 20, 2021
Personalizing Localized Prostate Cancer: Validation of a Combined Clinical Cell-cycle Risk (CCR) Score Threshold for Prognosticating Benefit From Multimodality Therapy
Jonathan D Tward, Thorsten Schlomm, Stephen Bardot, et al.
Personalized Medicine
|
September 5, 2019
Clinical outcomes in men with prostate cancer who selected active surveillance using a clinical cell cycle risk score
Sanjeev Kaul, Kirk J Wojno, Steven Stone, et al.
Frontiers in Neuroscience
|
March 15, 2024
Corpora amylacea negatively correlate with hippocampal tau pathology in Alzheimer's disease
Julian D Dallmeier, Ryan Gober, Regina T Vontell, et al.
Prostate Cancer and Prostatic Diseases
|
September 5, 2024
Active surveillance selection and 3-year durability in intermediate-risk prostate cancer following genomic testing
Lauren Lenz, Wyatt Clegg, Diana Iliev, et al.
The Journal of Urology
|
November 9, 2022
Reply by Authors
Bruce J Trock, Yuezhou Jing, Brent Mabey, et al.
The Journal of Urology
|
August 25, 2022
Cell Cycle Progression Score, but Not Phosphatase and Tensin Homolog Loss, Is an Independent Prognostic Factor for Metastasis in Intermediate- and High-risk Prostate Cancer in Men Treated With and Without Salvage Radiotherapy
Bruce J Trock, Yuezhou Jing, Brent Mabey, et al.
Biomarkers in Medicine
|
March 24, 2022
Development and validation of a cell cycle progression signature for decentralized testing of men with prostate cancer
Vanessa Kuhl, Wyatt Clegg, Stephanie Meek, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 41) with videos related to
Sort By:
Page
of 5
Journal of Pain and Symptom Management
|
June 12, 2021
Acupuncture as an Adjunctive Treatment for Pain in Hospitalized Children With Sickle Cell Disease
Sarah Reece-Stremtan, Laila Mahmood, Stefanie Margulies, et al.
Environmental Research
|
December 5, 2024
The environmental neuroactive chemicals list of prioritized substances for human biomonitoring and neurotoxicity testing: A database and high-throughput toxicokinetics approach
Julia E Rager, Lauren E Koval, Elise Hickman, et al.
Environmental Research
|
March 10, 2026
Corrigendum to 'The environmental neuroactive chemicals list of prioritized substances for human biomonitoring and neurotoxicity testing: A database and high-throughput toxicokinetics approach' [Environ. Res. 2025 (266) 120537]
Julia E Rager, Lauren E Koval, Elise Hickman, et al.
Clinical Genitourinary Cancer
|
February 20, 2021
Personalizing Localized Prostate Cancer: Validation of a Combined Clinical Cell-cycle Risk (CCR) Score Threshold for Prognosticating Benefit From Multimodality Therapy
Jonathan D Tward, Thorsten Schlomm, Stephen Bardot, et al.
Personalized Medicine
|
September 5, 2019
Clinical outcomes in men with prostate cancer who selected active surveillance using a clinical cell cycle risk score
Sanjeev Kaul, Kirk J Wojno, Steven Stone, et al.
Frontiers in Neuroscience
|
March 15, 2024
Corpora amylacea negatively correlate with hippocampal tau pathology in Alzheimer's disease
Julian D Dallmeier, Ryan Gober, Regina T Vontell, et al.
Prostate Cancer and Prostatic Diseases
|
September 5, 2024
Active surveillance selection and 3-year durability in intermediate-risk prostate cancer following genomic testing
Lauren Lenz, Wyatt Clegg, Diana Iliev, et al.
The Journal of Urology
|
November 9, 2022
Reply by Authors
Bruce J Trock, Yuezhou Jing, Brent Mabey, et al.
The Journal of Urology
|
August 25, 2022
Cell Cycle Progression Score, but Not Phosphatase and Tensin Homolog Loss, Is an Independent Prognostic Factor for Metastasis in Intermediate- and High-risk Prostate Cancer in Men Treated With and Without Salvage Radiotherapy
Bruce J Trock, Yuezhou Jing, Brent Mabey, et al.
Biomarkers in Medicine
|
March 24, 2022
Development and validation of a cell cycle progression signature for decentralized testing of men with prostate cancer
Vanessa Kuhl, Wyatt Clegg, Stephanie Meek, et al.
Page
of 5